4.3 Review

Platelet abnormalities in diabetes mellitus

Journal

DIABETES & VASCULAR DISEASE RESEARCH
Volume 7, Issue 4, Pages 251-259

Publisher

SAGE PUBLICATIONS LTD
DOI: 10.1177/1479164110383994

Keywords

Cardiovascular disease; diabetes mellitus; platelets

Funding

  1. Eli Lilly
  2. Daiichi Sankyo
  3. Bristol Myers Squibb
  4. Sanofi-Aventis
  5. Eli Lilly Co
  6. Daiichi Sankyo, Inc
  7. Medicines Company
  8. Portola
  9. Novartis
  10. Medicure
  11. Accumetrics
  12. Arena Pharmaceuticals
  13. Merck
  14. GlaxoSmithKline
  15. Otsuka
  16. Schering-Plough

Ask authors/readers for more resources

Patients with diabetes mellitus (DM) have accelerated atherosclerosis, which is the main underlying factor contributing to the high risk of atherothrombotic events in these patients Atherothrombotic complications are the leading cause of morbidity and mortality in patients with DM Among factors contributing to the prothrombotic condition which characterise patients with DM, platelet hyperreactivity plays a pivotal role Platelets of DM patients are characterised by dysregulation of several signalling pathways leading to intensified adhesion, activation and aggregation Multiple mechanisms are involved in platelet dysfunction of patients with DM, which can be categorised as follows a) hyperglycaemia, b) insulin deficiency and resistance, c) associated metabolic conditions, and d) other cellular abnormalities The present manuscript aims to provide an overview on the current status of knowledge on platelet abnormalities that characterise patients with DM

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available